A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.


Updates from The Motley Fool

Latest updates on Acorda Therapeutics from Fool.com.  The Fool has written over 100 articles on Acorda Therapeutics.
This Week in Biotech: Part 2

Four positive clinical trials had investors jumping for joy in the biotech sector this week.

Big Bets on MS

A review of the multiple sclerosis market.



Stock Performance

View Interactive ACOR Charts
Sponsored by

Key Data Points

Primary metrics and data points about Acorda Therapeutics.
Current Price: $24.90
Prev Close: $25.00
Open: $24.90
Bid: $24.50
Ask: $25.20
Day's Range: $24.35 - $25.15
52wk Range: $16.40 - $37.36
Volume: 416,167
Avg Vol 846,140
Market Cap: $1B
P/E (ttm): 100.00
EPS (ttm): $0.25
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Acorda Therapeutics.
CAPS Rating 3 out of 5
 
215 Outperform
89 Underperform
CAPS All Stars
 
40 Outperform
20 Underperform

How do you think Acorda Therapeutics will perform against the market?



You pick for Acorda Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Ron Cohen, CEO

72% Approve

Based on 16 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Acorda Therapeutics.

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers